Author

T. S. Dexheimer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

R. R. Neubig· 3 shared S. A. Misek· 3 shared E. M. Lisabeth· 2 shared K. M. Appleton· 2 shared S. D. Larsen· 2 shared B. R. Martin· 1 shared C. C. Palsuledesai· 1 shared D. A. Fox· 1 shared

Activity by Year

2018-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. R. Neubig

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines

K. M. Appleton, C. C. Palsuledesai, S. A. Misek, M. Blake, J. Zagorski, T. S. Dexheimer, R. R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-222740 enhances trametinib's effectiveness in NRAS-mutant melanoma cell lines by reducing cell viability and clonogenicity.

bioRxiv · Sep 19, 2019Cancer Biology

Rho-mediated gene transcription promotes BRAF inhibitor resistance in de-differentiated melanoma cells

S. A. Misek, K. M. Appleton, T. S. Dexheimer, E. M. Lisabeth, R. Lo, S. D. Larsen, K. Gallo, R. R. Neubig

This study identifies RhoA-mediated gene transcription as a mechanism of BRAF inhibitor resistance in melanoma, showing that targeting this pathway can re-sensitize resistant cells to vemurafenib.

bioRxiv · Mar 31, 2019 · PreprintCancer Biology

Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds

E. M. Lisabeth, D. Kahl, I. Gopallawa, S. E. Haynes, S. A. Misek, P. L. Campbell, T. S. Dexheimer, D. Khanna, D. A. Fox, X. Jin, B. R. Martin, S. D. Larsen, R. R. Neubig

This study identifies pirin as the molecular target of the CCG-1423/CCG-203971 compounds, showing its role in modulating MRTF-dependent gene expression and fibrosis.

bioRxiv · Oct 31, 2018Pharmacology & Toxicology